Fear of cancer progression in patients with stage IA malignant melanoma

Wagner, Tobias; Augustin, Matthias; Blome, Christine; Forschner, Andrea; Garbe, Claus; Gutzmer, Ralf; Hauschild, Axel; Heinzerling, Lucie; Livingstone, Elisabeth; Loquai, Carmen; Schadendorf, Dirk; Terheyden, Patrick; Mueller-Brenne, Tina; Kähler, Katharina C.

doi:10.1111/ecc.12901

Cited by 22 publications

(26 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The expanded use of HADS allows us to compare our results with that in other dermatologic diseases and beyond. HADS-A and HADS-D scores observed for MF in this study are in the range of scores reported for severe psoriasis ( 29 ) and are partly higher than in patients with malignant melanoma stage Ia ( 50 ). In comparison with non-dermatologic diseases, the HADS results of this study are in the range of values observed in adolescents with severe asthma, coronary arteria disease, or dialysis ( 51 – 53 ).…”

Section: Discussionsupporting

confidence: 61%

Quality of Life, Anxiety, and Depression in Patients With Early-Stage Mycosis Fungoides and the Effect of Oral Psoralen Plus UV-A (PUVA) Photochemotherapy on it

et al. 2020

View full text Add to dashboard Cite

Background: Little is known about psychological discomfort and quality of life (QoL) in early stage mycosis fungoides (MF) and the effect of psoralen plus UV-A (PUVA) on it. Objective: To evaluate QoL, anxiety, and depression with validated instruments in early stage MF patients and whether PUVA treatment improves it. Methods: Patients with stage IA to IIA MF were treated with PUVA twice weekly for 12-24 weeks, followed by maintenance treatment or not, in a prospective randomized clinical trial. Patients completed a questionnaire on DLQI as well as the Hospital Anxiety and Depression Scale (HADS) prior to therapy, after their last PUVA exposure, and after the PUVA maintenance or observance phase. Results: For 24 patients with early stage MF, completed questionnaires were available and analyzed. Prior to treatment, 17% reported strong (DLQI > 10) and 29% moderate impairment (DLQI 6-10) in QoL; 33% of patients reported HADS scores indicating anxiety, and 21% reported scores indicating depression. PUVA significantly improved overall QoL by reducing mean DLQI scores by 58.6% (p = 0.003), HADS-A by 30% (p = 0.045), and HADS-D by 44% (p = 0.002). Improvements in QoL and psychological well-being seemed to be sustained, irrespective of maintenance treatment or not. Limitations: Small sample size. Conclusions: PUVA sustainably improves QoL and psychological well-being in patients with early stage MF. Clinical trial registration: ClinicalTrials.gov identifier: NCT01686594.

show abstract

Section: Discussionsupporting

confidence: 61%

Quality of Life, Anxiety, and Depression in Patients With Early-Stage Mycosis Fungoides and the Effect of Oral Psoralen Plus UV-A (PUVA) Photochemotherapy on it

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Con respecto al nivel de estudios, la presencia de más casos de ansiedad en personas con estudios medios que con estudios superiores fue coherente con investigaciones previas. Estas resaltan que un mayor nivel de instrucción permitiría tener más información con respecto a la enfermedad, disminuyendo la incertidumbre y el miedo a la misma, situación que facilita la toma de decisiones y los recursos a utilizar, favoreciendo un mejor estado emocional 19,21,22 . Finalmente, se confirma que a más edad hay menos ansiedad, consistente con otros trabajos que resaltan que una enfermedad como el cáncer implica una amenaza al proyecto de vida por la incertidumbre con respecto a su evolución, originando un mayor malestar emocional en personas de menor edad al tenerlo menos desarrollado 36,31,42 .…”

Section: Discussionunclassified

“…Cuando se analiza la actividad laboral, se indica que el mantenimiento de una vida activa se asocia a un mejor estado emocional, lo que puede estar mediado por diferentes factores como un mejor nivel económico o sentimientos de utilidad 18 . En cuanto al estado civil y al nivel educativo, se ha indicado que estar casado o tener un mayor nivel de estudios serían factores protectores frente a problemas emocionales, al favorecer la percepción de apoyo social y la disponibilidad de más recursos para hacer frente a la enfermedad [19][20][21][22] . Finalmente, respecto a la edad, algunos estudios reportan una disminución de la probabilidad de desarrollar depresión conforme aumenta 23,24 , mientras otros señalan niveles más altos de depresión y ansiedad en pacientes mayores 21,25 .…”

unclassified

Estado emocional de pacientes oncológicos: evaluación de la ansiedad y la depresión en función de variables clínicas y sociodemográficas

2021

View full text Add to dashboard Cite

“…3. Criterion validity: Based on previous studies [19], the Hospital Anxiety and Depression Scale (HADS) and the shortened version of the SF-36 Health Survey (SF-12) were used to verify the criterion validity of the AP-FOP-Q-SF.…”

Section: Determination Of Questionnaire Itemsmentioning

confidence: 99%

Psychometric validation of the Fear of Progression Questionnaire-Short Form in acute pancreatitis patients (AP-FoP-Q-SF)

Siddique

Yang

Shengxiao

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: Fear of progression (FoP) is present in acute pancreatitis (AP) patients and has an impact on quality of life and self-management, but lack of assessment tools. This study therefore aimed to develop and evaluates the psychometric properties of the fear of Progression Questionnaire-Short Form in acute pancreatitis patients (AP-FoP-Q-SF). Besides, the cut-off score for high FoP and identification of patient characteristics associated with FoP.Methods: A prospective cross-sectional validation study was performed in 417 patients diagnosed with AP. Redundant items were systematically excluded. Internal consistency (Cronbach’s α), factorial structure (principal component analysis), convergent validity (confirmatory factor analysis), and criterion validity tested against quality-of-life and anxiety were assessed. A receiver operating characteristic (ROC) curve analysis was performed to identify the most appropriate cutoff value for high FoP.Associations between patient variables and FoP were evaluated using multiple logistic regression.Results: The AP-FoP-Q-SF based on the FoP-Q-SF were developed. Three items were excluded using item analysis. Exploratory and confirmatory factor analyses revealed a clear two-factor structure (57.4% explained variance). Internal consistency was acceptable (Cronbach’s α=0.771). The cutoff of 26 identified 35.3% of patients with high FoP scores. High FoP scores were associated with age (OR=0.96, 95%CI: 0.94-0.98), recurrence times (OR=1.22, 95%CI: 1.02-1.45) and anxiety (OR=1.27, 95%CI: 1.16-1.40).Conclusion: The AP-FoP-Q-SF is a good candidate for use as a screening tool for FoP in AP patients. Clinicians can use the AP-FoP-Q-SF to assess this kind of emotion and take promotion programs to avoid worse effects.

show abstract

Fear of cancer progression in patients with stage IA malignant melanoma

Cited by 22 publications

References 39 publications

Quality of Life, Anxiety, and Depression in Patients With Early-Stage Mycosis Fungoides and the Effect of Oral Psoralen Plus UV-A (PUVA) Photochemotherapy on it

Quality of Life, Anxiety, and Depression in Patients With Early-Stage Mycosis Fungoides and the Effect of Oral Psoralen Plus UV-A (PUVA) Photochemotherapy on it

Estado emocional de pacientes oncológicos: evaluación de la ansiedad y la depresión en función de variables clínicas y sociodemográficas

Psychometric validation of the Fear of Progression Questionnaire-Short Form in acute pancreatitis patients (AP-FoP-Q-SF)

Contact Info

Product

Resources

About